Research reference · 10 mg vial

Sermorelin (10 mg Vial) Dosage Protocol

Written by PeptideDosages Editorial Team Published Updated

This sermorelin dosage chart converts a 10 mg vial reconstituted with 3.0 mL into a 3.33 mg/mL concentration, then maps the page’s established 200–500 mcg calculation rows to both U-100 syringe units and milliliters. The chart preserves the existing schedule while distinguishing vial math from published clinical evidence.

On this page
  1. Quick reference
  2. Dosage chart and four steps
  3. Supplies needed
  4. Peptide Reconstitution Simulator
  5. Vial and research context
  6. Sermorelin 10 mg Vial and Research Context
  7. Sermorelin Dosage Research: What the Literature Shows
  8. Sermorelin Dosage Calculator: Units, mL, and mcg
  9. How Sermorelin Works
  10. Human Findings and Evidence Limits
  11. Safety, Storage, and Handling
  12. Sermorelin Dosage FAQ
  13. Research Use Notice
  14. References
  15. Related research, protocols, and guides

Sermorelin Quick Reference (10 mg Vial)

Vial contents
10 mg Sermorelin
Final volume
3 mL
Concentration
3.33 mg/mL
One U-100 unit
33.33 mcg in 0.01 mL
Sermorelin (10 mg Vial) Dosage Protocol peptide vial

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read Sermorelin Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Sermorelin Dosage Chart

Dosing & Reconstitution Guide

Educational guide for reconstitution and nightly dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week Daily Dose (µg) Units (per injection) (mL)
Weeks 1–2 200 µg (0.2 mg) 6 units (0.06 mL)
Weeks 3–4 300 µg (0.3 mg) 9 units (0.09 mL)
Weeks 5–6 400 µg (0.4 mg) 12 units (0.12 mL)
Weeks 7–8 500 µg (0.5 mg) 15 units (0.15 mL)

Frequency: Inject once daily subcutaneously at bedtime. Bedtime administration is strongly recommended because endogenous GH secretion peaks during sleep[3]. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units measurable with standard insulin syringes.

For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; gently swirl to dissolve (do not shake vigorously)[2].
  3. Label with reconstitution date and refrigerate at 2–8 °C (36–46 °F), protected from light[2][4].
  4. Wipe vial stopper with alcohol before each use; use a new sterile needle and syringe for each injection[2].

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–week daily protocol with gradual titration (56 injections total).

  • Peptide Vials (Sermorelin, 10 mg each):
    • 8 weeks (total ~19.6 mg consumed): 2 vials (20 mg total)
    • 12 weeks (similar daily range): 4 vials
    • Tip: Have 1 extra vial as backup in case of spillage or loss.
  • Insulin Syringes (U‑100):
    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes (recommend 1 × 100‑count box)
    • 12 weeks: 84 syringes (1 × 100‑count box)
    • Preferred: 0.3–0.5 mL size with 28G–31G needle, 5/16″ to 1/2″ length for subcutaneous use. Consider 30‑ or 50‑unit syringes for low‑dose weeks for improved precision.
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
    • 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
    • 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
    • Contains benzyl alcohol preservative; do not use if allergic.
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100‑count boxes

Sharps Container: One puncture‑proof disposal container for used needles (sufficient for 56+ syringes).


Sermorelin 10 mg

Sermorelin 10 mg

View Supplier
U-100 syringes

U-100 syringes

View Supplier
Bacteriostatic water

Bacteriostatic water

View Supplier
Alcohol swabs

Alcohol swabs

View Supplier

Peptide Reconstitution Simulator

Practice preparing this vial with the verified strength and final volume from this protocol.

Sermorelin Vial and Research Context

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
  • Typical daily range: 200–500 µg once daily at bedtime (gradual titration).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 µg on a U‑100 insulin syringe.
  • Storage: Lyophilized: refrigerate at 2–8 °C (36–46 °F); after reconstitution, refrigerate at 2–8 °C (36–46 °F) and follow the exact product’s labeled use-by instructions[4].

Sermorelin is a 29-amino-acid analog of human growth hormone-releasing hormone that stimulates growth hormone release from the anterior pituitary.[1] Historical approval and the strongest direct evidence concern pediatric growth-related use; current FDA materials do not identify an approved adult growth-hormone-deficiency dose.[5][6] This page keeps the 10 mg vial calculations, units, mL, frequency, and supplies visible while explaining those evidence limits.

Sermorelin 10 mg Vial and Research Context

A 10 mg sermorelin vial changes how concentration, volume, U-100 syringe markings, and supply totals are calculated. It does not create a different compound or establish a different clinical indication. The chart above uses 3.0 mL of bacteriostatic water, producing approximately 3.33 mg/mL. At that concentration, 1 U-100 unit equals 0.01 mL, or about 33.3 mcg of sermorelin.

The original branded sermorelin product, Geref, was historically approved for pediatric growth-related use and later discontinued; FDA records state that the discontinuation was not for safety or efficacy reasons.[2] FDA materials also distinguish that historical pediatric indication from adult use: no growth-hormone secretagogue is approved for adult growth hormone deficiency.[3]

The supplier card on this page identifies the corresponding 10 mg research vial and product provenance.[9] Supplier information is not used as scientific evidence for the dosage schedule.

Sermorelin Dosage Research: What the Literature Shows

Searches for a sermorelin dosage chart often combine several different questions: how much peptide is in the vial, how much diluent is added, how many milliliters are drawn, how those milliliters map to U-100 syringe units, and what schedules have actually been studied. Those questions should not be treated as interchangeable.

Questions about the dosage of sermorelin, a starting dose, or doses of sermorelin need a defined population and evidence source. The best-known clinical literature concerns children with idiopathic growth hormone deficiency. A published review reported limited evidence for once-daily subcutaneous sermorelin at 30 mcg/kg at bedtime, with height-velocity outcomes followed over months.[1] That weight-based pediatric research does not validate a universal adult dose, a bodybuilding protocol, or a weight-loss regimen.

Adult research is much thinner and includes diagnostic studies, mechanistic experiments, retrospective combinations, and trials of other GHRH analogs. Reviews of growth-hormone secretagogues emphasize that adult clinical-efficacy data remain limited.[6] The 200–500 mcg rows retained in this page’s primary table are therefore presented as a transparent calculation framework for this vial strength, not as an FDA-approved adult treatment schedule.

Sermorelin Dosage Calculator: Units, mL, and mcg

For a 10 mg vial mixed with 3.0 mL, the concentration is calculated as follows:

  • 10 mg ÷ 3.0 mL = 3.33 mg/mL (rounded).
  • 1 U-100 unit = 0.01 mL.
  • 3.33 mg/mL × 0.01 mL = 0.0333 mg, or about 33.3 mcg per unit.

This is why the table pairs every peptide amount with both units and mL. For example, 6 units is 0.06 mL and corresponds to approximately 200 mcg at this concentration. The conversion changes if the vial strength or diluent volume changes, even when the peptide name stays the same.

A calculator can verify arithmetic, but it cannot determine whether a research schedule is supported, appropriate, or safe. Evidence strength and vial math are separate questions.

How Sermorelin Works

Sermorelin is a synthetic peptide corresponding to the 1–29 amino-acid fragment of human growth hormone-releasing hormone and retains GHRH biological activity. Sermorelin stimulates receptors on the pituitary gland to release endogenous growth hormone rather than supplying human growth hormone directly. The result is a pulsatile release of growth hormone that remains subject to physiologic feedback.[1]

Controlled physiology experiments showed that GHRH(1–29) can produce a clear rise in circulating growth hormone in healthy volunteers.[4] The response depends on a functioning pituitary and is influenced by age, endocrine status, test conditions, and other factors. A mechanistic response should not be assumed to prove a specific clinical benefit.

Human Findings and Evidence Limits

Published human research does not support treating all sermorelin dosage searches as one evidence category. Studies of the effects of sermorelin and related compounds may measure growth hormone levels, insulin-like growth factor 1, body composition, fat loss, or muscle mass; those endpoints are not interchangeable:

  • Pediatric growth hormone deficiency: the historical evidence base is the most direct for sermorelin itself, but dosing was weight-based and the population was children with a diagnosed condition.[1]
  • Healthy adults and older adults: studies of GHRH or related analogs show endocrine responses, but compounds, doses, outcomes, and populations vary. A randomized study of a GHRH analog in older adults found increased nocturnal GH and IGF-1, while many body-composition outcomes did not change consistently across participants.[5]
  • Adult performance or body-composition claims: contemporary reviews describe interest in secretagogues but also emphasize the limited clinical data and the need for better controlled trials.[6]

These differences matter when evaluating terms such as sermorelin dosage for men, sermorelin dosage for muscle growth, or sermorelin dosage for weight loss. Search popularity does not turn those phrases into validated indications.

Safety, Storage, and Handling

The common side effects of sermorelin reported in the historical literature included transient facial flushing, injection-site pain, and possible swelling at the injection site, while broader growth-hormone-axis research raises questions about endocrine and metabolic effects that depend on the compound, exposure, and population.[1][6]

Reconstituted sermorelin should be kept refrigerated and protected from freezing, with the exact product label or lot-specific documentation controlling storage and discard instructions.[7] Bacteriostatic water does not by itself establish a universal beyond-use period for a mixed peptide vial.

For general injection technique, administering sermorelin via subcutaneous injection requires a new sterile needle and syringe, rotating injection sites, and placing used sharps immediately into a puncture-resistant sharps container.[8] These handling principles do not validate the research schedule.

Sermorelin Dosage FAQ

How many U-100 units are in a sermorelin dose?

Units depend on both the peptide amount and the reconstitution volume. On this page, a 10 mg vial mixed with 3.0 mL contains about 33.3 mcg per U-100 unit. Six units is 0.06 mL, 9 units is 0.09 mL, 12 units is 0.12 mL, and 15 units is 0.15 mL.

Is a U-100 unit the same as a peptide IU?

No. U-100 syringe units are volume markings. They indicate hundredths of a milliliter, not international units of sermorelin activity.

Does a 10 mg vial change the sermorelin compound?

No. Vial strength changes the amount available and the concentration after mixing. It does not create a different molecule or prove a different research protocol.

Is there an approved adult sermorelin dosage?

No FDA-approved adult growth-hormone-deficiency dose exists for sermorelin. FDA materials note that the historical approval concerned pediatric short stature associated with growth hormone deficiency and that no growth-hormone secretagogue is approved for adult GHD.[3]

Why do sermorelin dosage charts differ online?

Pages may use different vial strengths, dilution volumes, populations, evidence categories, or community calculation examples. A responsible chart should make the vial amount, concentration, mcg, mL, syringe units, frequency, and evidence limits visible together.

Research Use Notice

This page explains published research and vial calculations for educational purposes. It is not medical advice and does not establish a recommended human dose. The retained chart is a calculation example for the 10 mg vial and should be interpreted separately from FDA-approved labeling and clinical evidence.

References

  • 1
    Prakash A, Goa KL. BioDrugs (1999) — Review of sermorelin pharmacology, pediatric growth-hormone-deficiency research, studied dosing, and reported adverse events.
    View Source
  • 2
    RxList — Sermorelin acetate monograph with historical administration, handling, and adverse-effect information.
    View Source
  • 3
    Khorram O, et al. J Clin Endocrinol Metab (1997) — Randomized, placebo-controlled research on nightly administration of a GHRH(1–29) analog in older adults.
    View Source
  • 4
    Mayo Clinic — Sermorelin injection storage and proper-use information.
    View Source
  • 5
    U.S. FDA Orange Book — Geref/sermorelin acetate discontinued product listing; federal determination notes it was not withdrawn for safety or efficacy reasons.
    View Source
  • 6
    U.S. FDA PCAC materials (2024) — Regulatory context for growth-hormone secretagogues, historical pediatric sermorelin approval, and the absence of an approved adult-GHD secretagogue.
    View Source
  • 7
    Losa M, et al. Klin Wochenschr (1984) — Controlled study of growth-hormone responses to human GRF fragments, including GRF(1–29).
    View Source
  • 8
    Jain SH, et al. Transl Androl Urol (2020) — Review of growth-hormone secretagogues, proposed mechanisms, adult evidence, and important limitations.
    View Source
  • 9
    Johns Hopkins Arthritis Center — General subcutaneous injection and sharps-disposal guidance.
    View Source
  • 10
    Pure Lab Peptides — Approved supplier/product-provenance page for the Sermorelin 10 mg research vial shown in the supplier card.
    View Source

Related research, protocols, and guides

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.

Research overview

Other vial-size protocols

Practical guides